Biochemistry, Genetics and Molecular Biology
B Cell
12%
Cancer Cell
18%
Cell Cycle Checkpoint
15%
Cell Cycle Progression
11%
Cell Growth
23%
Cell Metabolism
8%
Cell Proliferation
20%
Cell Survival
8%
Cellular Differentiation
8%
Clinical Trial
15%
Cooperation
7%
Copurification
17%
Cotransformation
17%
DNA Damage
19%
DNA Damage Response
7%
DNA Gyrase
17%
DNA Methylation
17%
Fibroblast
17%
Gene Expression
15%
Gene Ontology
8%
Granulocyte Colony-Stimulating Factor
20%
Histone Gene
17%
Homeostasis
7%
Liquid
17%
MAD1
34%
Malignant Transformation
20%
Mammalian Target of Rapamycin Complex 1
17%
Methylation
21%
Mouse
26%
Myc
9%
Myeloid
17%
Nucleolus
28%
P53
60%
Phosphoinositide 3-Kinase
11%
Polymerase
66%
Promoter Region
28%
Protein Biosynthesis
23%
Ribosomal DNA
22%
Ribosome Biogenesis
23%
RNA
17%
RNA Gene
29%
RNA Polymerase I
85%
RNA Polymerase II
17%
RNA Sequence
17%
RNA Translation
17%
Signal Transduction
7%
Transcription
100%
Transcription Factors
25%
Transcription Initiation
17%
Wild Type
9%
Medicine and Dentistry
Acute Myeloid Leukemia
6%
Ataxia Telangiectasia
6%
Biogenesis
32%
Cancer Therapy
23%
Cell Cycle Checkpoint
8%
Cell Growth
9%
Cell Proliferation
10%
Chromatin Structure
5%
Clinical Trial
8%
Combination Therapy
28%
Deacetylation
17%
Disease
28%
DNA Damage
9%
Drug Delivery System
5%
Epileptic Absence
5%
Everolimus
5%
Fibrillarin
5%
Fluorouracil
5%
Gemcitabine
5%
Genetic Transcription
5%
Hematologic Malignancy
14%
Malignant Neoplasm
53%
Mammalian Target of Rapamycin Complex 1
17%
Neoplasm
10%
Nucleolin
5%
Nucleolus
34%
Osteosarcoma
17%
Pancreas Adenocarcinoma
17%
Phosphoinositide 3-Kinase
8%
Polymerase
18%
Programmed Cell Death
5%
Prostate Cancer
5%
Protein P53
35%
Protein Synthesis
18%
Ribosome
52%
Ribosome DNA
22%
RNA Gene
5%
RNA Polymerase I
44%
RNA Translation
17%
Survival Rate
8%
Transcription Initiation
17%
Tumor Cell
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
38%
Adverse Event
7%
Alkyne
17%
Antitumor Activity
8%
Azide
17%
Biotin
17%
Chemotherapy
10%
Clinical Trial
7%
Combination Therapy
10%
Disease
23%
DNA Directed RNA Polymerase
98%
DNA Topoisomerase (ATP Hydrolysing)
17%
Drug Delivery System
5%
Epileptic Absence
5%
Fluorouracil
5%
Gemcitabine
5%
Hematologic Malignancy
18%
Leukemia
23%
Malignant Neoplasm
62%
Mouse
19%
Neoplasm
20%
Osteosarcoma
17%
Pancreas Adenocarcinoma
17%
Pharmacokinetics
8%
Prostate Cancer
5%
Protein P53
46%
Ribosome DNA
64%
Ribosome RNA
14%
RNA Polymerase
17%
Survival Rate
7%